Frazier Life Sciences Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Frazier Life Sciences Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.4M	Hold	1,438,198	–	–	0.79%	25
2026 Q1	$32M	Buy	1,438,198 +141,000	+11%	+$3.37M	0.82%	24
2025 Q4	$34.6M	Buy	1,297,198 +683,361	+111%	+$16.3M	0.93%	23
2025 Q3	$13.1M	Buy	+613,837	New	+$14.5M	0.39%	36
2025 Q2	–	Sell	-470,338	Closed	-$7.81M	–	50
2025 Q1	$7.81M	Hold	470,338	–	–	0.36%	34
2024 Q4	$8.63M	Hold	470,338	–	–	0.36%	38
2024 Q3	$7.23M	Hold	470,338	–	–	0.29%	45
2024 Q2	$7.64M	Hold	470,338	–	–	0.36%	40
2024 Q1	$8.7M	Sell	470,338 -260,579	-36%	-$6.46M	0.37%	42
2023 Q4	$22.9M	Buy	730,917 +100,020	+16%	+$2.39M	1.22%	23
2023 Q3	$13.1M	Sell	630,897 -226,441	-26%	-$6.15M	0.87%	29
2023 Q2	$20.5M	Hold	857,338	–	–	1.23%	20
2023 Q1	$16.1M	Hold	857,338	–	–	1.17%	23
2022 Q4	$13.6M	Hold	857,338	–	–	0.85%	23
2022 Q3	$14M	Buy	+857,338	New	+$13.9M	1.08%	22

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Frazier Life Sciences Management's ACAD Position: Q2 2026 in Review

Frazier Life Sciences Management held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 1,438,198 shares worth $36.4M. The position accounts for 0.79% of the portfolio, ranked #25.

Frazier Life Sciences Management first reported a position in ACAD in Q3 2022 and has held it in 15 quarters since. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Frazier Life Sciences Management held 1,438,198 shares of Acadia Pharmaceuticals worth $36.4M as of Q2 2026.
Frazier Life Sciences Management left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
Acadia Pharmaceuticals made up 0.79% of Frazier Life Sciences Management's portfolio in Q2 2026, its #25 holding.
Frazier Life Sciences Management first reported a position in Acadia Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.